Abstract : Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.
Type de document :
Article dans une revue
Human vaccines & immunotherapeutics. (Hum Vaccin Immunother), 2015-: Philadelphia, PA : Taylor & Francis, 2016, 〈10.1080/21645515.2016.1241358〉
https://hal-pasteur.archives-ouvertes.fr/pasteur-01579663
Contributeur : Anne Lassailly-Bondaz
<>
Soumis le : jeudi 31 août 2017 - 14:54:58
Dernière modification le : jeudi 31 août 2017 - 14:55:35
Document(s) archivé(s) le : vendredi 1 décembre 2017 - 18:30:00
Eva Hong, Aude Terrade, Muhamed-Kheir Taha. Human Vaccines & Immunotherapeutics Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Human vaccines & immunotherapeutics. (Hum Vaccin Immunother), 2015-: Philadelphia, PA : Taylor & Francis, 2016, 〈10.1080/21645515.2016.1241358〉. 〈pasteur-01579663〉
